drugset / Trial / NCT00433732

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

NCT00433732

Phase 3 Completed 1400 enrolled POZEN
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary endpoints.

Timeline

Start
2004-08
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 500 mg
Subject Sumatriptan Unknown 85 mg

Indications